Obesity
12
Companies
18
Drug Programs
8
Phase 3
0
Upcoming PDUFAs
Novo Nordisk A/S
Semaglutide 1.0 mg
Eli Lilly and Company
Retatrutide
Sanofi
rimonabant (SR141716)
MetaVia Inc.
DA-1726
Roche Holding AG
RO7204239
Hansoh Pharma
olatorepatide
HeartSciences Inc.
Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet
Eli Lilly
retatrutide
Sanofi
SR147778
Ionis Pharmaceuticals, Inc.
ISIS-FGFR4RX
Skye Bioscience, Inc.
Nimacimab injection
Novo Nordisk
liraglutide
Roche Holding
ALK7 RNAi obesity therapy
Eli Lilly
Unknown obesity drug
Corbus Pharmaceuticals
CRB-913
Artelo Biosciences
Oral dual cannabinoid agonist
Eli Lilly
Zepbound
Amgen
MariTide
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| NVO Novo Nordisk A/S | Semaglutide 1.0 mg | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | Retatrutide | Phase 3 | — | — | — |
| SNY Sanofi | rimonabant (SR141716) | Phase 3 | — | — | — |
| MTVA MetaVia Inc. | DA-1726 | Phase 3 | — | — | — |
| RHHBY Roche Holding AG | RO7204239 | Phase 3 | — | — | — |
| HNPHY Hansoh Pharma | olatorepatide | Phase 3 | — | — | — |
| HSCSW HeartSciences Inc. | Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet | Phase 3 | — | — | — |
| LLY Eli Lilly | retatrutide | Phase 3 | — | — | — |
| SNY Sanofi | SR147778 | Phase 2 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ISIS-FGFR4RX | Phase 2 | — | — | — |
| SKYE Skye Bioscience, Inc. | Nimacimab injection | Phase 2 | — | — | — |
| NVO Novo Nordisk | liraglutide | — | — | — | — |
| RHHBY Roche Holding | ALK7 RNAi obesity therapy | — | — | — | — |
| LLY Eli Lilly | Unknown obesity drug | — | — | — | — |
| CRBP Corbus Pharmaceuticals | CRB-913 | — | — | — | — |
| ARTL Artelo Biosciences | Oral dual cannabinoid agonist | — | — | — | — |
| LLY Eli Lilly | Zepbound | — | — | — | — |
| AMGN Amgen | MariTide | — | — | — | — |
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.